AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16522911 — intervention group
Group type: EXPERIMENTAL
Intervention: MDFP in wheat-based meal with ascorbic acid (4:1 molar ratio)
Number of subjects: 26
Study 16522911 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate in wheat-based meal with ascorbic acid (4:1 molar ratio)
Number of subjects: 26
Study 16522911 — intervention group
Group type: EXPERIMENTAL
Intervention: MDFP added to rice meal at feeding time
Number of subjects: 26
Study 16522911 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate in rice meal
Number of subjects: 26
Study 16522911 — intervention group
Group type: EXPERIMENTAL
Intervention: MDFP extruded into artificial rice grains
Number of subjects: 26
Study 16522911 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate in unprocessed rice
Number of subjects: 26
Study 12546349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate
Number of subjects: 957
Study 10665553 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (target international normalised ratio 3.0‐4.5, n=1339)
Number of subjects: 2690
Study 10665553 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (80 mg daily, n=1351)
Number of subjects: 2690
Study 9065637 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty supplemented with anterior inferior turbinoplasty
Number of subjects: 50
Study 9065637 — intervention group
Group type: COMPARATOR
Intervention: Septoplasty alone
Number of subjects: 50
Study 8373269 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-cm surgical margins
Number of subjects: 486
Study 8373269 — intervention group
Group type: COMPARATOR
Intervention: 4-cm surgical margins
Number of subjects: 486
Study 31035391 — intervention group
Group type: EXPERIMENTAL
Intervention: High RF‐EMF (2 W/kg)
Number of subjects: 36
Study 31035391 — intervention group
Group type: EXPERIMENTAL
Intervention: Low RF‐EMF (1 W/kg)
Number of subjects: 36
Study 31035391 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 36
Study 28812448 — intervention group
Group type: COMPARATOR
Intervention: Control condition of an ongoing cluster-randomised controlled trial
Number of subjects: 20
Study 27115063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified bread (FP; 50 g bread fortified with 25 μg vitamin D3 plus placebo daily; n = 30)
Number of subjects: 90
Study 27115063 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement (SP; 50 g plain bread plus 25 μg vitamin D supplement daily; n = 30)
Number of subjects: 90
Study 27115063 — intervention group
Group type: COMPARATOR
Intervention: Control (CP; 50 g plain bread plus placebo daily; n = 30)
Number of subjects: 90
Study 24650128 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre supplement (HFS)
Number of subjects: 107
Study 24650128 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre diet (HFD)
Number of subjects: 107
Study 24650128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 22155490 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy lunch (922 cal)
Number of subjects: 12
Study 22155490 — intervention group
Group type: COMPARATOR
Intervention: Light lunch (305 cal)
Number of subjects: 12
Study 20300966 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 2000
Study 20300966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB) procedure
Number of subjects: 2000
Study 19192435 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (37.5 mg/day - 300 mg/day, N = 340)
Number of subjects: 687
Study 19192435 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 347)
Number of subjects: 687
Study 19192435 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 687
Study 15862926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium-lactate infusion
Number of subjects: 0
Study 15862926 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline infusion
Number of subjects: 0
Study 12162507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone-replacement therapy (HRT)
Number of subjects: 429
Study 12162507 — intervention group
Group type: EXPERIMENTAL
Intervention: FokI polymorphism
Number of subjects: 429
Study 12162507 — intervention group
Group type: EXPERIMENTAL
Intervention: BsmI polymorphism
Number of subjects: 429
Study 12162507 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 429
Study 12162507 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype (FF and BB)
Number of subjects: 429
Study 10337463 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IFN alpha vaccine
Number of subjects: 242
Study 10337463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 10337463 — intervention group
Group type: COMPARATOR
Intervention: Non-responder vaccinees
Number of subjects: 242
Study 8563585 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisterplase 30 units given intravenously before hospitalisation
Number of subjects: 311
Study 8563585 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisterplase 30 units given intravenously later in hospital
Number of subjects: 311
Study 1681913 — intervention group
Group type: EXPERIMENTAL
Intervention: Impermeable nonwoven drapes with self‐adhesive edges
Number of subjects: 61
Study 1681913 — intervention group
Group type: COMPARATOR
Intervention: Permeable linen drapes sealed to the skin with self‐adhesive nonwoven tape
Number of subjects: 61
Study 6358329 — intervention group
Group type: EXPERIMENTAL
Intervention: META (15 mg)
Number of subjects: 0
Study 6358329 — intervention group
Group type: EXPERIMENTAL
Intervention: ATR (2 mg)
Number of subjects: 0
Study 6358329 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO (125 micrograms)
Number of subjects: 0
Study 6358329 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 0
Study 31523872 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline survey
Number of subjects: 933
Study 31523872 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up survey (mean = 3.6 days post-baseline)
Number of subjects: 933
Study 31523872 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs measured
Number of subjects: 933
Study 31523872 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline drug use
Number of subjects: 933
Study 31523872 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey location (outside of festivals vs nightclubs)
Number of subjects: 933
Study 28245970 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV.sFlt‐1 subretinal injection (low-dose: 1 × 10^10 vector genomes; high-dose: 1 × 10^11 vector genomes)
Number of subjects: 8
Study 28245970 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab
Number of subjects: 8
Study 26077862 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric surgery (PS)
Number of subjects: 38
Study 26077862 — intervention group
Group type: COMPARATOR
Intervention: Drilling
Number of subjects: 38
Study 24714414 — intervention group
Group type: EXPERIMENTAL
Intervention: H.P. Acthar(®) Gel (40 or 80 IU subcutaneously twice weekly)
Number of subjects: 20
Study 24714414 — intervention group
Group type: EXPERIMENTAL
Intervention: H.P. Acthar(®) Gel
Number of subjects: 20
Study 21540583 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose PUFAs, polyphenols and L-carnitine (PPC)
Number of subjects: 22
Study 21540583 — intervention group
Group type: COMPARATOR
Intervention: Low-fat yoghurt (Control)
Number of subjects: 22
Study 19843790 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 group
Number of subjects: 66
Study 19843790 — intervention group
Group type: COMPARATOR
Intervention: PEEP 5 group
Number of subjects: 66
Study 19843790 — intervention group
Group type: COMPARATOR
Intervention: ZEEP group
Number of subjects: 66
Study 17259872 — intervention group
Group type: EXPERIMENTAL
Intervention: HA vaccine (HAVRIX; Glaxo SmithKline) 720 EL.U., administered in group 1 at ages 6 and 12 months
Number of subjects: 248
Study 17259872 — intervention group
Group type: EXPERIMENTAL
Intervention: HA vaccine (HAVRIX; Glaxo SmithKline) 720 EL.U., administered in group 2 at ages 12 and 18 months
Number of subjects: 248
Study 17259872 — intervention group
Group type: EXPERIMENTAL
Intervention: HA vaccine (HAVRIX; Glaxo SmithKline) 720 EL.U., administered in group 3 at ages 15 and 21 months
Number of subjects: 248
Study 17259872 — intervention group
Group type: EXPERIMENTAL
Intervention: HA vaccine (HAVRIX; Glaxo SmithKline) 720 EL.U., administered in group 1 (6 and 12 months) vs group 3 (15 and 21 months)
Number of subjects: 248
Study 17259872 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccinations administered during infancy
Number of subjects: 248
Study 15539847 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyrus Plasmasect TURP
Number of subjects: 117
Study 15539847 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURP
Number of subjects: 117
Study 11449083 — intervention group
Group type: EXPERIMENTAL
Intervention: 28.5 mg/day of isoflavones
Number of subjects: 46
Study 11449083 — intervention group
Group type: EXPERIMENTAL
Intervention: 57 mg/day of isoflavones
Number of subjects: 46
Study 11449083 — intervention group
Group type: EXPERIMENTAL
Intervention: 85.5 mg/day of isoflavones
Number of subjects: 46
Study 11449083 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of isoflavones
Number of subjects: 46
Study 9684075 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative drops of commercially available combination tobramycin-dexamethasone drops at 15 minute intervals
Number of subjects: 32
Study 9684075 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen shield soaked in tobramycin-dexamethasone
Number of subjects: 32
Study 8030449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonal oral contraceptive containing 75 μg gestodene plus 30 μg ethinyl estradiol
Number of subjects: 69
Study 2977262 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg Zoladex depot subcutaneous injection every 28 days for 12 weeks
Number of subjects: 90
Study 2977262 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg Zoladex depot subcutaneous injection every 28 days for 12 weeks
Number of subjects: 90
Study 2977262 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mg Zoladex depot subcutaneous injection every 28 days for 12 weeks
Number of subjects: 90
Study 2977262 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex treatment (all doses)
Number of subjects: 90
Study 31091612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (salt reduction activities for 8 months)
Number of subjects: 2724
Study 31091612 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2724
Study 28989150 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg, 5 mL) during general anesthesia induction, post-operative day 1 and day 2
Number of subjects: 40
Study 28989150 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (5 mL) at corresponding time points
Number of subjects: 40
Study 27101674 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium tablets combined with budesonide nasal spray and desloratadine citrate disodium tablets for 4 weeks
Number of subjects: 70
Study 27101674 — intervention group
Group type: COMPARATOR
Intervention: Budensonide nasal spray and desloratadine citrate disodium tablets for 4 weeks
Number of subjects: 70
Study 23563958 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Number of subjects: 186
Study 23563958 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 150 mg/m(2)
Number of subjects: 186
Study 23563958 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel 100 mg/m(2)
Number of subjects: 186
Study 21440700 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT)
Number of subjects: 64
Study 21440700 — intervention group
Group type: COMPARATOR
Intervention: Bimanual training
Number of subjects: 64
Study 20088415 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Chinese herbal decoction plus western medicine (Group A)
Number of subjects: 80
Study 20088415 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Group B)
Number of subjects: 80
Study 20088415 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Chinese herbal decoction (Group C)
Number of subjects: 80
Study 20088415 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone (Group D)
Number of subjects: 80
Study 16681469 — intervention group
Group type: EXPERIMENTAL
Intervention: Erectile Dysfunction (ED) patients
Number of subjects: 69
Study 16681469 — intervention group
Group type: COMPARATOR
Intervention: Moderate ED
Number of subjects: 69
Study 14749231 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA + LA supplementation (2.8 g ALA + 9.0 g LA)
Number of subjects: 58
Study 14749231 — intervention group
Group type: COMPARATOR
Intervention: LA supplementation (10.9 g LA)
Number of subjects: 58
Study 11689273 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg per day
Number of subjects: 29
Study 11689273 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (pooled group)
Number of subjects: 29
Study 11689273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9451517 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms intravaginal misoprostol
Number of subjects: 65
Study 9451517 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg intracervical gel of dinoprostone
Number of subjects: 65
Study 9451517 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 65
Study 8198235 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with alginate-conjugated extract of Parietaria judaica
Number of subjects: 35
Study 8198235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 3127432 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl (10 and 40 mg/day)
Number of subjects: 17
Study 3127432 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine (mean dose, 16 mg/day)
Number of subjects: 17
Study 3127432 — intervention group
Group type: COMPARATOR
Intervention: L-deprenyl
Number of subjects: 17
Study 30773796 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intracoronary thrombolysis (pro‐urokinase and anisodamine via catheter)
Number of subjects: 39
Study 30773796 — intervention group
Group type: COMPARATOR
Intervention: Thrombus aspiration (TA)
Number of subjects: 39
Study 30773796 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intracoronary thrombolysis (TCA)
Number of subjects: 39
Study 30773796 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TCA and TA
Number of subjects: 39
Study 30096952 — intervention group
Group type: EXPERIMENTAL
Intervention: L. paracasei KW3110-containing supplements for eight weeks
Number of subjects: 62
Study 30096952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 26813755 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical traction combined with extension-oriented exercises
Number of subjects: 120
Study 26813755 — intervention group
Group type: COMPARATOR
Intervention: Extension-oriented exercises alone
Number of subjects: 120
Study 24261771 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (100 mg/dose, twice daily)
Number of subjects: 70
Study 24261771 — intervention group
Group type: COMPARATOR
Intervention: Loxoprofen (60 mg/dose, 3 times daily)
Number of subjects: 70
Study 24261771 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 70
Study 24261771 — intervention group
Group type: COMPARATOR
Intervention: Loxoprofen
Number of subjects: 70
Study 21953376 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g CMC-001 (manganese-based contrast agent)
Number of subjects: 20
Study 21953376 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mmol/kg gadobenate dimeglumine (intravenous contrast agent)
Number of subjects: 20
Study 21953376 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC-001 (manganese-based contrast agent)
Number of subjects: 20
Study 21953376 — intervention group
Group type: COMPARATOR
Intervention: gadobenate dimeglumine (intravenous contrast agent)
Number of subjects: 20
Study 20633071 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil antiseptic mouthrinse (EOM)
Number of subjects: 22
Study 20633071 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 22
Study 17155972 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical periprostatic block with 5 mL of 1% lidocaine
Number of subjects: 143
Study 17155972 — intervention group
Group type: COMPARATOR
Intervention: Basal periprostatic block with 5 mL of 1% lidocaine
Number of subjects: 143
Study 15883575 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 109
Study 15883575 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 109
Study 15002499 — intervention group
Group type: EXPERIMENTAL
Intervention: Head out of water immersion (HOI) at two different temperatures in sitting position
Number of subjects: 0
Study 15002499 — intervention group
Group type: EXPERIMENTAL
Intervention: Head out of water immersion (HOI) at two different temperatures in standing position
Number of subjects: 0
Study 15002499 — intervention group
Group type: COMPARATOR
Intervention: Microgravity during parabolic flight
Number of subjects: 0
Study 10401901 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine patient-controlled analgesia with ketorolac
Number of subjects: 0
Study 10401901 — intervention group
Group type: COMPARATOR
Intervention: Morphine patient-controlled analgesia without ketorolac (placebo)
Number of subjects: 0
Study 7726582 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreen (SPF 17)
Number of subjects: 113
Study 7726582 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 113
Study 2365458 — intervention group
Group type: EXPERIMENTAL
Intervention: Leish vaccine 5 or Leish vaccine 6 with or without Corynebacterium parvum
Number of subjects: 0
Study 2365458 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 2365458 — intervention group
Group type: EXPERIMENTAL
Intervention: Leish vaccine 5
Number of subjects: 0
Study 94089 — intervention group
Group type: EXPERIMENTAL
Intervention: RAI treatment while on antithyroid drugs after attainment of euthyroidism
Number of subjects: 24
Study 94089 — intervention group
Group type: COMPARATOR
Intervention: No antithyroid drugs before or when RAI was given
Number of subjects: 24
Study 31868311 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium toothbrush group (n = 34)
Number of subjects: 80
Study 31868311 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft toothbrush group (n = 38)
Number of subjects: 80
Study 31868311 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 80
Study 29215909 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational intervention designed to increase supervisor social support and job control
Number of subjects: 420
Study 29215909 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 420
Study 28387919 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D with intensive drugs
Number of subjects: 124
Study 28387919 — intervention group
Group type: COMPARATOR
Intervention: Intensive drugs (Control)
Number of subjects: 124
Study 26335438 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Contrasting and Implementation Intentions (MCII)
Number of subjects: 36
Study 26335438 — intervention group
Group type: COMPARATOR
Intervention: Equal contact goal intention control condition (informative text about physical activity)
Number of subjects: 36
Study 26335438 — intervention group
Group type: EXPERIMENTAL
Intervention: MCII
Number of subjects: 36
Study 26335438 — intervention group
Group type: COMPARATOR
Intervention: Equal contact goal intention control condition
Number of subjects: 36
Study 25142565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonomat
Number of subjects: 62
Study 25142565 — intervention group
Group type: COMPARATOR
Intervention: PSG
Number of subjects: 62
Study 22383739 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CIS)
Number of subjects: 498
Study 22383739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus tirapazamine (TPZ/CIS)
Number of subjects: 498
Study 19561548 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic mixture
Number of subjects: 0
Study 19561548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17804329 — intervention group
Group type: EXPERIMENTAL
Intervention: gutta percha with AH Plus (Dentsply, DeTrey, Germany)
Number of subjects: 25
Study 17804329 — intervention group
Group type: EXPERIMENTAL
Intervention: gutta percha with Kerr EWT (Kerr Corp, Romulus, MI)
Number of subjects: 25
Study 17804329 — intervention group
Group type: EXPERIMENTAL
Intervention: Activ GP (Brasseler) obturation system
Number of subjects: 25
Study 17804329 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon (Pentron Clinical Technologies, Wallingford, CT) and Epiphany (Pentron)
Number of subjects: 25
Study 17804329 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoREZ obturation system (Ultradent, South Jordan, UT)
Number of subjects: 25
Study 15090740 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (400 mg/day for 2 years)
Number of subjects: 30
Study 15090740 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UFT treatment)
Number of subjects: 30
Study 11419108 — intervention group
Group type: EXPERIMENTAL
Intervention: New antihypertensive drugs (angiotensin-converting enzyme inhibitors, calcium-antagonists, alpha-blockers)
Number of subjects: 58000
Study 11419108 — intervention group
Group type: COMPARATOR
Intervention: Old antihypertensive drugs (thiazide diuretics, beta-blockers)
Number of subjects: 58000
Study 9526938 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.2 microg/kg/min
Number of subjects: 107
Study 9526938 — intervention group
Group type: COMPARATOR
Intervention: Propofol 100 microg/kg/min
Number of subjects: 107
Study 9526938 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 107
Study 9526938 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 107
Study 8017151 — intervention group
Group type: EXPERIMENTAL
Intervention: Device 1
Number of subjects: 72
Study 8017151 — intervention group
Group type: EXPERIMENTAL
Intervention: Device 2
Number of subjects: 72